Posted in | News | Nanobusiness

BioForce Nanosciences Strengthens Focus on Emerging Technologies

BioForce Nanosciences, Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc., announced today a new division to the Company. As of July 15, Dr. Saju Nettikadan is director of the “Emerging Technologies” division of BioForce. Dr. Nettikadan will oversee the division dedicated to commercializing in-house research and development efforts, enabling collaborations with external R&D consumers of BioForce's instruments. Dr. Nettikadan has been an integral employee of BioForce for nearly nine years and has been the project director for the previously publicized ViriChip™ platform and Chip-on-a-Tip™ projects. He holds a doctorate from The Ohio State University.

BioForce Nanosciences develops and commercializes nanotech tools and solutions for the life sciences. BioForce’s flagship product, the Nano eNabler™ molecular printer, gives the Company a unique platform for development and discovery. Anticipated scientific applications developed within the BioForce laboratory or in user’s laboratories have the potential for significant future revenue.

BioForce’s President and Chief Operating Officer Kerry Frey noted, “It’s very exciting to be at a point in BioForce’s progression to be seeing results with the Nano eNabler™ system sales and anticipating increased results from our heightened focus on Emerging Technologies.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.